Made from concentrate? A national web survey assessing dab use in the United States

Drug and Alcohol Dependence

Volumn 190, Issue , 2018, Pages 133-142

  Sagar, Kelly A ^a,b,c,d   Lambros, Ashley M ^a,b   Dahlgren, Mary Kathryn ^a,b   Smith, Rosemary T ^a,b   Gruber, Staci A ^a,b,c  

^a McLean Brain Imaging Center   (United States)

^b MCLEAN HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cannabis; Concentrates; Dabs; Marijuana; Potency; Survey; THC

Indexed keywords

ADULT; AFRICAN AMERICAN; AMERICAN INDIAN; ARTICLE; ASIAN; CANNABIS USE; CAUCASIAN; CONSUMER; CONTROLLED STUDY; DESCRIPTIVE RESEARCH; FEMALE; HISPANIC; HUMAN; INFORMATION PROCESSING; INFORMED CONSENT; MALE; MARIJUANA MOTIVES MEASURE AND SEVERITY OF DEPENDENCE SCALE; MULTIRACIAL PERSON; PACIFIC ISLANDER; PRIORITY JOURNAL; QUESTIONNAIRE; UNITED STATES; ANXIETY; CANNABIS ADDICTION; DRUG THERAPY; MIDDLE AGED; PSYCHOLOGY;

CANNABIS; DIAZOBENZENESULFONIC ACID; DIAZONIUM COMPOUND; DRONABINOL; SULFANILIC ACID DERIVATIVE;

ADULT; ANXIETY; CANNABIS; DIAZONIUM COMPOUNDS; DRONABINOL; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; MIDDLE AGED; SULFANILIC ACIDS; SURVEYS AND QUESTIONNAIRES; UNITED STATES;

EID: 85049908673     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2018.05.022     Document Type: Article

References (30)

1. Bhattacharyya, S., Morrison, P.D., Fusar-Poli, P., Martin-Santos, R., Borgwardt, S., Winton-Brown, T., Nosarti, C., O'Carroll, C.M., Seal, M., Allen, P., Mehta, M.A., Stone, J.M., Tunstall, N., Giampietro, V., Kapur, S., Murray, R.M., Zuardi, A.W., Crippa, J.A., Atakan, Z., McGuire, P.K., Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35 (2010), 764–774, 10.1038/npp.2009.184.
2. Carlini, B.H., Garrett, S.B., Harwick, R.M., Beyond joints and brownies: marijuana concentrates in the legal landscape of WA State. Int. J. Drug Policy 42 (2017), 26–29, 10.1016/j.drugpo.2017.01.004.
3. Cavazos-Rehg, P.A., Sowles, S.J., Krauss, M.J., Agbonavbare, V., Grucza, R., Bierut, L., A content analysis of tweets about high-potency marijuana. Drug Alcohol Depend. 166 (2016), 100–108, 10.1016/j.drugalcdep.2016.06.034.
4. Chait, L.D., Delta-9-tetrahydrocannabinol content and human marijuana self-administration. Psychopharmacology (Berl.) 98 (1989), 51–55.
5. Chan, G.C.K., Hall, W., Freeman, T.P., Ferris, J., Kelly, A.B., Winstock, A., User characteristics and effect profile of butane hash oil: an extremely high-potency cannabis concentrate. Drug Alcohol Depend. 178 (2017), 32–38, 10.1016/j.drugalcdep.2017.04.014.
6. D'Souza, D.C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., Wu, Y.T., Braley, G., Gueorguieva, R., Krystal, J.H., The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29 (2004), 1558–1572, 10.1038/sj.npp.1300496.
7. Daniulaityte, R., Nahhas, R.W., Wijeratne, S., Carlson, R.G., Lamy, F.R., Martins, S.S., Boyer, E.W., Smith, G.A., Sheth, A., “Time for dabs”: analyzing Twitter data on marijuana concentrates across the U.S. Drug Alcohol Depend. 155 (2015), 307–311, 10.1016/j.drugalcdep.2015.07.1199.
8. Daniulaityte, R., Lamy, F.R., Barratt, M., Nahhas, R.W., Martins, S.S., Boyer, E.W., Sheth, A., Carlson, R.G., Characterizing marijuana concentrate users: a web-based survey. Drug Alcohol Depend. 178 (2017), 399–407, 10.1016/j.drugalcdep.2017.05.034.
9. Di Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M., Bianconi, F., Gardner-Sood, P., O'Connor, J., Russo, M., Stilo, S.A., Marques, T.R., Mondelli, V., Dazzan, P., Pariante, C., David, A.S., Gaughran, F., Atakan, Z., Iyegbe, C., Powell, J., Morgan, C., Lynskey, M., Murray, R.M., Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. Lancet Psychiatry 2 (2015), 233–238, 10.1016/s2215-0366(14)00117-5.
10. ElSohly, M.A., Mehmedic, Z., Foster, S., Gon, C., Chandra, S., Church, J.C., Changes in cannabis potency over the last 2 decades (1995-2014): analysis of current data in the United States. Biol. Psychiatry 79 (2016), 613–619, 10.1016/j.biopsych.2016.01.004.
11. Freeman, T.P., Winstock, A.R., Examining the profile of high-potency cannabis and its association with severity of cannabis dependence. Psychol. Med. 45 (2015), 3181–3189, 10.1017/S0033291715001178.
12. Freeman, T.P., Morgan, C.J., Hindocha, C., Schafer, G., Das, R.K., Curran, H.V., Just say’ know’: how do cannabinoid concentrations influence users’ estimates of cannabis potency and the amount they roll in joints?. Addiction 109 (2014), 1686–1694, 10.1111/add.12634.
13. Fusar-Poli, P., Crippa, J.A., Bhattacharyya, S., Borgwardt, S.J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S.A., O'Carrol, C., Atakan, Z., Zuardi, A.W., McGuire, P.K., Distinct effects of delta-9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch. Gen. Psychiatry 66 (2009), 95–105, 10.1001/archgenpsychiatry.2008.519.
14. Keller, C.J., Chen, E.C., Brodsky, K., Yoon, J.H., A case of butane hash oil (marijuana wax)-induced psychosis. Subst. Abus. 37 (2016), 384–386, 10.1080/08897077.2016.1141153.
15. Kowal, M.A., Hazekamp, A., Colzato, L.S., van Steenbergen, H., van der Wee, N.J., Durieux, J., Manai, M., Hommel, B., Cannabis and creativity: highly potent cannabis impairs divergent thinking in regular cannabis users. Psychopharmacology (Berl.) 232 (2015), 1123–1134, 10.1007/s00213-014-3749-1.
16. Large, M., Nielssen, O., Daily use of high-potency cannabis is associated with an increased risk of admission and more intervention after first-episode psychosis. Evid. Based Ment. Health, 20, 2017, 58, 10.1136/eb-2017-102630.
17. Loflin, M., Earleywine, M., A new method of cannabis ingestion: the dangers of dabs?. Addict. Behav. 39 (2014), 1430–1433, 10.1016/j.addbeh.2014.05.013.
18. Meier, M.H., Associations between butane hash oil use and cannabis-related problems. Drug Alcohol Depend. 179 (2017), 25–31, 10.1016/j.drugalcdep.2017.06.015.
19. Pierre, J.M., Gandal, M., Son, M., Cannabis-induced psychosis associated with high potency “wax dabs. Schizophr. Res. 172 (2016), 211–212, 10.1016/j.schres.2016.01.056.
20. Piontek, D., Kraus, L., Klempova, D., Short scales to assess cannabis-related problems: a review of psychometric properties. Subst. Abuse Treat. Prev. Policy, 3, 2008, 25, 10.1186/1747-597X-3-25.
21. Raber, J.C., Elzinga, S., Kaplan, C., Understanding dabs: contamination concerns of cannabis concentrates and cannabinoid transfer during the act of dabbing. J. Toxicol. Sci. 40 (2015), 797–803, 10.2131/jts.40.797.
22. Ramaekers, J.G., Kauert, G., van Ruitenbeek, P., Theunissen, E.L., Schneider, E., Moeller, M.R., High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 31 (2006), 2296–2303, 10.1038/sj.npp.1301068.
23. Rigucci, S., Marques, T.R., Di Forti, M., Taylor, H., Dell'Acqua, F., Mondelli, V., Bonaccorso, S., Simmons, A., David, A.S., Girardi, P., Pariante, C.M., Murray, R.M., Dazzan, P., Effect of high-potency cannabis on corpus callosum microstructure. Psychol. Med. 46 (2016), 841–854, 10.1017/S0033291715002342.
24. Simons, J., Correia, C.J., Carey, K.B., Borsari, B.E., Validating a five-factor marijuana motives measure: relations with use, problems, and alcohol motives. J. Couns. Psychol. 45 (1998), 265–273, 10.1037/0022-0167.45.3.265.
25. Smart, R., Caulkins, J.P., Kilmer, B., Davenport, S., Midgette, G., Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addiction 112 (2017), 2167–2177, 10.1111/add.13886.
26. Stogner, J.M., Miller, B.L., Assessing the dangers of “dabbing”: Mere marijuana or harmful new trend?. Pediatrics 136 (2015), 1–3, 10.1542/peds.2015-0454.
27. van der Pol, P., Liebregts, N., Brunt, T., van Amsterdam, J., de Graaf, R., Korf, D.J., van den Brink, W., van Laar, M., Cross-sectional and prospective relation of cannabis potency, dosing and smoking behaviour with cannabis dependence: an ecological study. Addiction 109 (2014), 1101–1109, 10.1111/add.12508.
28. Winton-Brown, T.T., Allen, P., Bhattacharyya, S., Borgwardt, S.J., Fusar-Poli, P., Crippa, J.A., Seal, M.L., Martin-Santos, R., Ffytche, D., Zuardi, A.W., Atakan, Z., McGuire, P.K., Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study. Neuropsychopharmacology 36 (2011), 1340–1348, 10.1038/npp.2011.17.
29. Zhang, Z., Zheng, X., Zeng, D.D., Leischow, S.J., Tracking dabbing using search query surveillance: a case study in the United States. J. Med. Internet Res., 18, 2016, e252, 10.2196/jmir.5802.
30. Zuurman, L., Ippel, A.E., Moin, E., van Gerven, J.M., Biomarkers for the effects of cannabis and THC in healthy volunteers. Br. J. Clin. Pharmacol. 67 (2009), 5–21, 10.1111/j.1365-2125.2008.03329.x.